Compare Genmab A/S with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 105,622 Million ()
16.00
NA
0.00%
-0.88
18.89%
2.84
Revenue and Profits:
Net Sales:
5,722 Million
(Quarterly Results - Mar 2026)
Net Profit:
338 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.96%
0%
-8.96%
6 Months
-12.87%
0%
-12.87%
1 Year
29.73%
0%
29.73%
2 Years
-14.5%
0%
-14.5%
3 Years
-40.31%
0%
-40.31%
4 Years
-15.76%
0%
-15.76%
5 Years
-23.24%
0%
-23.24%
Genmab A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.34%
EBIT Growth (5y)
5.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.46
Tax Ratio
13.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
125.56%
ROE (avg)
18.85%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.96
EV to EBIT
16.21
EV to EBITDA
16.21
EV to Capital Employed
2.22
EV to Sales
5.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.67%
ROE (Latest)
18.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
5,721.60
5,067.90
12.90%
Operating Profit (PBDIT) excl Other Income
1,436.80
1,332.50
7.83%
Interest
715.20
35.40
1,920.34%
Exceptional Items
-287.40
0.00
Consolidate Net Profit
338.40
1,382.20
-75.52%
Operating Profit Margin (Excl OI)
251.10%
262.90%
-1.18%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 12.90% vs 22.32% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -75.52% vs 4.32% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
24,600.40
21,526.00
14.28%
Operating Profit (PBDIT) excl Other Income
8,735.80
7,416.00
17.80%
Interest
403.40
120.00
236.17%
Exceptional Items
-1,223.40
-300.00
-307.80%
Consolidate Net Profit
6,368.30
7,844.00
-18.81%
Operating Profit Margin (Excl OI)
336.00%
325.30%
1.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.28% vs 30.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -18.81% vs 80.24% in Dec 2024
About Genmab A/S 
Genmab A/S
Pharmaceuticals & Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Coordinates 
Company Details
Kalvebod Brygge 43 , KOEBENHAVN V None : 1560
Registrar Details






